Envoy Medical's Newly Published Peer-Reviewed Article In The Current Otorhinolaryngology Reports Highlights Advances In Fully Implanted Cochlear Implant Technology

6/5/24 8:06:19 AM ET

Industrial Specialties

Health Care

Get the next $COCH alert in real time by email

Envoy Medical in Position to Leverage its Sensor Technology

WHITE BEAR LAKE, MN, June 05, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today highlighted a recently published article in the Current Otorhinolaryngology Reports. The article, titled, "Fully Implanted Cochlear Implants," was authored by Dr. Eric Babajanian, Dr. James Dornhoffer, and Dr. Colin Driscoll from Mayo Clinic in Rochester, Minnesota. Authors describe it as a review of the current state of fully implanted cochlear implants, including some of the challenges, limitations and breakthroughs.

Get the next $COCH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$COCH

Date	Price Target	Rating	Analyst
6/24/2024	$8.50	Buy	Ascendiant Capital Markets

More analyst ratings

$COCH
Financials

Live finance-specific insights

Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events
WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events. "The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing devices. First, we have received FDA's approval to start our pivotal trial of the Acclaim® fully implanted cochlear implant ("Acclaim CI"). Second, we continue to make tremendous
11/14/24 8:38:22 AM ET
$COCH
Industrial Specialties
Health Care
Envoy Medical Reports Second Quarter 2024 Results and Provides Business Update
Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough fully implanted Acclaim® cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year WHITE BEAR LAKE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the second quarter ended June 30, 2024. "We are pleased with the steady progress that Envoy Medical has made this quarter and year-to-date in advancing our goal of becoming a leading cochle
8/12/24 8:34:07 AM ET
$COCH
Industrial Specialties
Health Care
Envoy Medical Reports First Quarter 2024 Results
The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its "breakthrough" fully implanted cochlear implant. WHITE BEAR LAKE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the first quarter ended March 31, 2024. Financial and Corporate Highlights from Q1 2024 All three participants in the ongoing Early Feasibility Study (EFS) at Mayo Clinic (Rochester, MN) have completed their 12-m
5/15/24 4:05:42 PM ET
$COCH
Industrial Specialties
Health Care

$COCH
Press Releases

Fastest customizable press release news feed in the world

Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events
WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events. "The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing devices. First, we have received FDA's approval to start our pivotal trial of the Acclaim® fully implanted cochlear implant ("Acclaim CI"). Second, we continue to make tremendous
11/14/24 8:38:22 AM ET
$COCH
Industrial Specialties
Health Care
Envoy Medical's Fully Implanted Acclaim® Cochlear Implant Highlighted in Peer-Reviewed Publication
Study in Otology & Neurotology outlines early experiences and potential benefits of breakthrough fully implanted cochlear implant WHITE BEAR LAKE, Minnesota , Nov. 12, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announces a peer-reviewed publication in Otology & Neurotology, discussing early experiences with and highlighting potential benefits of the Company's investigational fully implanted Acclaim® Cochlear Implant (Acclaim CI). The paper, titled, "Early Hearing Outcomes and Audiological Experiences with a Novel Fully Implanted Cochlear Implant," discusses the initial result
11/12/24 9:25:00 AM ET
$COCH
Industrial Specialties
Health Care
Envoy Medical Receives Another European Patent for its Modular Cochlear Implant System
WHITE BEAR LAKE, Minnesota, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announces that the European Patent Office has granted the Company Patent No. 3858425, titled," Implantable Modular Cochlear Implant System with Communication System and Network." The patent relates to a modular cochlear implant system configured to receive input signals from an implantable source and a wireless receiving device and output a stimulation signal based on the received input signals and a programmable mixing ratio representative of the relative contributions of the input signals to th
11/8/24 9:25:00 AM ET
$COCH
Industrial Specialties
Health Care

Envoy Medical's Newly Published Peer-Reviewed Article In The Current Otorhinolaryngology Reports Highlights Advances In Fully Implanted Cochlear Implant Technology

Chat with this insight

Recent Analyst Ratings for $COCH

$COCH Financials

Live finance-specific insights

Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events

Envoy Medical Reports Second Quarter 2024 Results and Provides Business Update

Envoy Medical Reports First Quarter 2024 Results

$COCH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Patel Mona Chetan bought $5,699 worth of shares (2,500 units at $2.28), increasing direct ownership by 50% to 7,500 units (SEC Form 4)

Director Kantor Susan acquired 18,182 shares, increasing direct ownership by 73% to 43,182 units (SEC Form 4)

Large owner Anzu Spac Gp I Llc disposed of 1,000,000 shares (SEC Form 4)

$COCH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Ascendiant Capital Markets initiated coverage on Envoy Medical with a new price target

$COCH Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Envoy Medical Inc.

SEC Form SC 13G filed by Envoy Medical Inc.

$COCH Market Insights

Live Market Insights

Envoy Medical Joins Russell Microcap Index

Envoy Medical shares are trading higher after Ascendiant Capital initiated coverage with a Buy rating and announced a price target of $8.50.

Ascendiant Capital Initiates Coverage On Envoy Medical with Buy Rating, Announces Price Target of $8.5

$COCH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Patel Mona Chetan bought $5,699 worth of shares (2,500 units at $2.28), increasing direct ownership by 50% to 7,500 units (SEC Form 4)

Director Patel Mona Chetan bought $16,520 worth of shares (5,000 units at $3.30) (SEC Form 4)

$COCH Press Releases

Fastest customizable press release news feed in the world

Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events

Envoy Medical's Fully Implanted Acclaim® Cochlear Implant Highlighted in Peer-Reviewed Publication

Envoy Medical Receives Another European Patent for its Modular Cochlear Implant System

$COCH Leadership Updates

Live Leadership Updates

Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

Envoy Medical to Host Fireside Chat Event December 7

$COCH SEC Filings

Envoy Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 424B3 filed by Envoy Medical Inc.

SEC Form 424B3 filed by Envoy Medical Inc.

Recent Analyst Ratings for
$COCH

$COCH
Financials

$COCH
Insider Trading

$COCH
Analyst Ratings

$COCH
Large Ownership Changes

$COCH
Market Insights

$COCH
Insider Purchases

$COCH
Press Releases

$COCH
Leadership Updates

$COCH
SEC Filings